RXi Pharmaceuticals said this week that it has formed a collaboration with the University of Massachusetts Medical School's Shalesh Kaushal to develop the company's self-delivering RNAi molecules as therapeutics for ocular diseases.
Conditions that will be a focus of the deal include age-related macular degeneration, RXi said.
Specific terms of the arrangement were not disclosed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
